

PROPOSED CONFERENCE PROGRAM

DAY 1

10:00 - 11:00	Inaugural Ceremony - India Pharma and India Medical Devices Annual Conference (Launch of Knowledge Report)	
11:00 - 11:15	Tea Break	
11:15 - 13:30	INDIA PHARMA CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	IP Workshop 01: Jan Aushadhi Initiative
13:30 - 14:30	Lunch break	
14:30 - 15:30	India Medical Devices CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	IP Workshop 02: In association with IPC on harmacovigilance
15:30 - 15:45	Tea Break	
15:45 - 16:45	Regulators Meet: Industry interaction with Central & State Drug Regulators	
16:45 - 17:15	Tea Break	
17:15 - 18:30	States Investment Session	
19:30 Onwards	Dinner hosted by Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Gol (By Invitation Only)	

DAY 2

10:00 - 11:30	IP 01: India as a Vaccine Manufacturing Destination & Biosimilars: Driving Innovation, Affordability, and Global Competitiveness in Healthcare	
11:30 - 11:45	Tea Break	
11:45 - 13:00	IP 02: Pharma Moonshots: Pioneering Innovation and Transformative R&D for the Future	Start-up Pitching Session
13:00 - 14:00	Lunch Break	
14:00 - 15:30	IP 03: Contract Research and Manufacturing: Catalyzing Growth for India Pharma's Global Reach	Global Partnership Enhancing India Pharmaceuticals industry
15:30 - 15:45	Tea Break	
16:00 - 17:30	Valedictory Session	

DAY 1	
Time	Sessions
10:00 - 11:00	Inaugural Session: 9th Edition of India Pharma and India Medical Device Annual Conference
11:00 - 11:15	Tea Break
11:15 - 13:30	INDIA PHARMA CEO Roundtable with Hon'ble Minister for Chemicals & Fertilizers, Dept of Pharmaceuticals with Government of India (By Invitation Only)
11:15 - 13:30	<p>IP Workshop 01: Jan Aushadhi Initiative</p> <p>Workshop Brief Details and Objectives:-</p> <p>The Jan Aushadhi initiative is a transformative effort to provide affordable generic medicines, significantly reducing healthcare costs for consumers. With over 10,000 Jan Aushadhi Kendras across India, offering more than 800 medicines and 154 surgical items at prices at least 50% cheaper, the program has led to an estimated annual savings of ₹ 10,000 crore for consumers. By setting maximum retail prices, ensuring high-quality standards, and eliminating intermediaries in procurement and distribution, the initiative enhances accessibility and trust. Additional incentives, financial support for manufacturers, and public awareness campaigns further bolster the impact of this program, empowering both consumers and healthcare providers.</p> <p>Expected Outcome</p> <p>Participants will gain a comprehensive understanding of the Jan Aushadhi initiative's impact on reducing healthcare costs and improving access to affordable medicines, and will identify actionable strategies to further enhance outreach, efficiency, and public awareness.</p>
13:30 - 14:30	Lunch Break
14:30-15:30	India Medical Devices CEO Roundtable with Hon'ble Minister of Health & Family Welfare and Chemicals & Fertilizers, Government of India (By Invitation Only)
Parallel	<p>IP Workshop 02: Workshop in association with IPC on Pharmacovigilance</p> <p>Workshop Brief Details and Objectives:-</p> <p>Workshop on Pharmacovigilance: Ensuring Drug Safety</p> <p>This workshop will focus on the critical role of pharmacovigilance in monitoring and improving drug safety. The workshop on pharmacovigilance will offer a comprehensive exploration of key topics essential for ensuring drug safety and patient well-being. These will include the importance of pharmacovigilance in safeguarding patient safety, best practices for adverse drug reaction (ADR) reporting systems, and adherence to regulatory compliance and global safety standards. Participants will also engage with case studies showcasing effective pharmacovigilance implementation in real-world settings. Designed for healthcare professionals, researchers, and regulatory authorities, the workshop aims to enhance expertise in drug safety monitoring, foster collaboration across stakeholders, and promote a culture of patient-centred care.</p>

	<p>Expected Outcome</p> <p>Participants will develop a deeper understanding of pharmacovigilance principles, ADR reporting systems, and regulatory compliance, enabling them to implement effective drug safety practices and contribute to a patient-centric approach in healthcare delivery.</p>
15:30 - 15:45	Tea Break
15:45 - 16:45	<p>Regulators Meet: Industry interaction with Central & State Drug Regulators</p> <p>This interaction will facilitate a constructive dialogue on enhancing the regulatory framework for the pharmaceuticals and medical devices sectors in our country. It will focus on identifying and adopting effective regulatory practices to foster mutual alignment, enabling the establishment of collaborative channels for superior trade, regulation, and manufacturing environments. The interaction between industry representatives and regulators will centre on proactive discussions to address industry concerns, strengthen synergies, and ensure optimal compliance while encouraging the development of safe and effective drugs and products. this regulators meet will entail Critical challenges in the Pharma sector hindering growth., strategies to address regulatory barriers affecting import/export activities, establishing mechanisms for extended dialogue between regulators to enhance knowledge sharing and skill development, opportunities and obstacles in achieving regulatory harmonization and potential role of state drug regulators in driving sectoral growth.</p> <p>Expected Outcome: The session will feature a question-and-answer format, allowing industry representatives to seek clarifications and raise specific concerns directly with regulators. It provides a platform for open dialogue, enabling stakeholders to voice their issues and contribute to shaping effective regulatory frameworks. This interaction fosters mutual understanding, promotes compliance, and drives continuous improvement in the pharmaceutical sector.</p>
16:45 - 17:15	Tea Break
17:15 - 18:30	<p>States Investment Session</p> <p>Session Brief:</p> <p>India's \$50 billion pharmaceutical industry, projected to expand to \$450 billion by 2047, is a global leader and a top destination for investors. Renowned as the "pharmacy of the world," India supplies medicines to over 200 countries. This session will delve into the diverse investment opportunities in the pharma sector. Facilitate strategic dialogue between industry and state governments to identify investment opportunities, improve supply chain integration through manufacturing and innovation in the sector, promote the benefits and opportunities in Bulk Drug Parks, establish an affordable and accessible pharma ecosystem in India to collectively improve public health outcomes, and extend opportunities for knowledge sharing between the government and industry to enhance the scope of the industry. The session will briefly have objective to highlight pharma manufacturing opportunities across Indian states, promotion of Bulk Drug Parks, showcase of state-specific investment opportunities and incentives for pharmaceutical companies, Strengthen collaborations between state governments and the pharmaceutical industry to enhance linkages.</p> <p>Expected Outcome: To showcase investment opportunities and development prospects across Indian states in the pharmaceutical sector, encompassing generics, APIs, biosimilars, CRAMS, and digital health. It will explore government initiatives such as PLI schemes and regulatory reforms designed to attract investments and accelerate industry growth. Additionally, the session will foster strategic partnerships and collaborations among investors, industry leaders, and government stakeholders to drive innovation and development in the sector.</p>
19:30 Onwards	Dinner hosted by Minister

Day 2

10:00 - 11:30

IP 01: India as a Vaccine Manufacturing Destination & Biosimilars: Driving Innovation, Affordability, and Global Competitiveness in Healthcare

Session Brief:

India has positioned itself as a global powerhouse in vaccine manufacturing, producing 60% of the world's vaccines and supplying to over 150 countries. The country's vaccine market is expected to reach \$2.4 billion in 2025, growing at a CAGR of 18%. India's vaccine production landscape, comprising more than 30 major manufacturers, has proven its capability to innovate and mass-produce cost-effective, high-quality vaccines. This was successfully demonstrated during the COVID-19 pandemic with India supplying vaccines to 1.4 billion people in India and 242 million to 101 other countries. This session will explore India's strengths in vaccine manufacturing, including its robust infrastructure, skilled workforce, and cost-effective production. Biosimilars are transforming healthcare by driving innovation, enhancing affordability, and boosting global competitiveness. These biologic products offer cost-effective alternatives to expensive reference biologics, improving patient access to critical therapies for chronic and life-threatening diseases. By fostering innovation in manufacturing processes and regulatory frameworks, biosimilars are not only reducing healthcare costs but also positioning India as a global leader in biopharmaceutical production.

Expected Outcomes: This session aims to explore how collaboration and strategic dialogue can tackle industry challenges, leverage opportunities, and adapt to emerging trends. Key areas of focus include effective vaccine deployment, disease prevention, and critical policy measures. The discussion seeks to improve patient access to healthcare, drive economic growth, and strengthen India's global competitiveness while enhancing the ease of doing business. The session will further explore strategies to scale biosimilar adoption, promote investments, and enhance collaboration between industry and government to unlock their full potential in delivering equitable healthcare solutions worldwide.

11:30 - 11:45

Tea Break

11:45 - 13:00

IP 02: Pharma Moonshots: Pioneering Innovation and Transformative R&D for the Future

Session Brief:

In an era defined by rapid technological advancements and evolving healthcare demands, the Indian pharmaceutical industry has a pivotal role in shaping the future of global healthcare. As the largest producer of generic medicines, India has significantly contributed to affordable healthcare worldwide. However, maintaining this leadership requires a paradigm shift towards innovation-driven research and transformative R&D. This session will delve into the critical need for India to foster cutting-edge pharmaceutical innovation, focusing on breakthrough therapies, advanced manufacturing, and novel drug development. It will explore actionable strategies to strengthen the industry's global competitiveness, address pressing healthcare challenges such as accessibility and affordability, and align with sustainable growth goals.

Expected Outcome: This session will explore the global healthcare landscape, focusing on innovations in biopharmaceuticals, biosimilars, digital health, nanotechnology, and personalized medicine. It will highlight strategies to accelerate growth through policy support and incentives, positioning India as a leader in both generics and cutting-edge pharmaceutical advancements.

Parallel	<p>Start-up Pitching Session</p> <p>Session Brief:</p> <p>The Biotech & Pharma Startup Pitch Session is a vibrant platform designed to spotlight groundbreaking biotech and pharmaceutical startups while fostering collaborations, securing funding, and advancing national health priorities. This event brings together a diverse audience, including startups, pharma giants, venture capitalists, government officials, and healthcare professionals, to drive innovation in areas such as drug development, digital health, personalized medicine, and affordable healthcare. By showcasing transformative ideas, facilitating partnerships, and aligning with regulatory and access challenges, the session aims to catalyze impactful solutions that address critical healthcare needs, offering unparalleled opportunities for innovators, investors, and stakeholders to collaborate on shaping the future of health.</p> <p>Expected Outcome:</p> <p>Interactive sessions with investors and mentors will provide selected startups with valuable networking opportunities, enabling them to connect with potential investors, strategic partners, and industry experts to accelerate their growth and success.</p>
13:00 - 14:00	Lunch Break
14:00 - 15:30	<p>IP 03: Contract Research and Manufacturing: Catalyzing Growth for India Pharma's Global Reach</p> <p>Brief session flow:</p> <p>This session highlights the critical role of contract research and manufacturing services (CRAMS) in expanding the global footprint of the Indian pharmaceutical industry. It will delve into strategies to enhance CRAMS capabilities, foster innovation, and build robust international partnerships. Key discussions will focus on leveraging India's expertise in drug development and manufacturing, scaling operations to meet global quality standards, overcoming supply chain challenges, and unlocking collaboration opportunities with global pharma players. Participants will gain valuable insights into industry trends, market demands, and success stories, reinforcing India's position as a trusted partner in the global healthcare ecosystem and driving sustained growth in international markets.</p> <p>Expected outcomes: This session will provide insights into scaling CRAMS operations to meet global standards, fostering innovation, and building international partnerships. The session will equip stakeholders to address supply chain challenges, leverage India's expertise, and seize collaboration opportunities with global pharma players. These outcomes aim to position India as a leading partner in the global healthcare ecosystem, driving sustained growth and market expansion.</p>
Parallel	<p>Global Partnership Enhancing India Pharmaceuticals industry</p> <p>Session Brief:</p> <p>Globalization has enabled numerous Indian pharmaceutical companies to extend their operations internationally. Shifts in regulatory, patent, and market trends are creating significant opportunities for generic drugs, positioning Indian pharma companies to capitalize on these prospects in the global marketplace. However, many Indian pharmaceutical companies face substantial challenges in global markets. The session will help to deliberate on key aspects to boost Global Partnerships Enhancing India's Pharmaceuticals Sector. These include the identification of Global Best Practices, Market Diversification, Technology Transfer and R&D Collaborations process bottlenecks that impede investments for pharma industry. A related point of focus will be the Improved Compliance, Global Regulatory Overview: Presentations by International Regulators on their regulatory frameworks, latest updates and areas of focus sharing within the Pharma sector, where various stakeholders collaborate to optimize resources and capabilities. Taking a broader perspective, the global dimension of pharma sector will be considered, examining global mechanisms to catalyse this industry.</p> <p>Expected Outcome: To address global bottlenecks in regulatory alignment, this session will emphasize the importance of mutual recognition agreements and strategies to overcome trade barriers. Through an interactive dialogue, participants will engage in an open discussion on the regulatory challenges, market access hurdles, and trade barriers faced by the pharmaceutical industry, particularly in regulated markets. The session aims to identify actionable solutions to enhance India's global competitiveness and streamline market entry for Indian pharma companies.</p>
15:30 - 15:45	Tea Break
16:00 - 17:30	Valedictory Session